Matches in Nanopublications for { ?s ?p "[Rarity of second-hit inactivation of the involved gene in CHEK2-, NBN/NBS1- and BLM-associated BC demonstrates their substantial biological difference from BRCA1/2-driven cancers and makes them poorly suitable for the clinical trials with cisplatin and PARP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP1144263.RAqjdt0PkACyou9pBs28o0MhwSIXs4MPGu-3IBzep4Gt0130_assertion description "[Rarity of second-hit inactivation of the involved gene in CHEK2-, NBN/NBS1- and BLM-associated BC demonstrates their substantial biological difference from BRCA1/2-driven cancers and makes them poorly suitable for the clinical trials with cisplatin and PARP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1144263.RAqjdt0PkACyou9pBs28o0MhwSIXs4MPGu-3IBzep4Gt0130_provenance.
- NP1144260.RAMadERLPVQ6WqracjFOFQDLw4qKAjjZfxx3xRKfn_jPc130_assertion description "[Rarity of second-hit inactivation of the involved gene in CHEK2-, NBN/NBS1- and BLM-associated BC demonstrates their substantial biological difference from BRCA1/2-driven cancers and makes them poorly suitable for the clinical trials with cisplatin and PARP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1144260.RAMadERLPVQ6WqracjFOFQDLw4qKAjjZfxx3xRKfn_jPc130_provenance.
- NP1144261.RA9upu1dAR82zTnKOQtTcGdRfHkBz_X_aoT0syiHF_1Ts130_assertion description "[Rarity of second-hit inactivation of the involved gene in CHEK2-, NBN/NBS1- and BLM-associated BC demonstrates their substantial biological difference from BRCA1/2-driven cancers and makes them poorly suitable for the clinical trials with cisplatin and PARP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1144261.RA9upu1dAR82zTnKOQtTcGdRfHkBz_X_aoT0syiHF_1Ts130_provenance.